Established Medical Therapy for Benign Prostatic Hyperplasia

被引:88
作者
Auffenberg, Gregory B. [1 ]
Helfand, Brian T. [1 ]
McVary, Kevin T. [1 ]
机构
[1] Northwestern Univ, Dept Urol, Feinberg Sch Med, Chicago, IL 60611 USA
关键词
Benign prostatic hyperplasia; 5-alpha reductase inhibitor; Alpha-blocker; Anti-cholinergic; Phytotherapeutics; LOWER URINARY-TRACT; SAW PALMETTO EXTRACTS; PYGEUM-AFRICANUM EXTRACT; SERENOA-REPENS EXTRACT; DOUBLE-BLIND; COMBINATION THERAPY; MESSENGER-RNA; ALPHA(1A)-ADRENOCEPTOR-SELECTIVE ANTAGONIST; HUMAN ALPHA(1)-ADRENOCEPTORS; 5-ALPHA-REDUCTASE TYPE-1;
D O I
10.1016/j.ucl.2009.07.004
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Benign prostatic hyperplasia is characterized by smooth muscle and epithelial proliferation primarily within the prostatic transition zone that can cause a variety of problems for a patient, the most frequent being bothersome lower urinary tract symptoms. In most cases, medical therapy has become the first-line treatment modality of choice, with a variety of pharmacologic mechanisms proving to be beneficial. Several large trials have shown the efficacy of alpha-receptor blocking and 5-alpha reductase inhibiting medications when used alone and in combination. Newer data has shown the benefit of anti-muscarinic medications in specific populations who suffer from bladder outlet obstruction causing storage urinary symptoms. Phytotherapeutic supplements are numerous and used frequently; however, data supporting safety and efficacy is limited, making treatment recommendations difficult. The available clinical trial data for all of these types of therapy is discussed in this article.
引用
收藏
页码:443 / +
页数:19
相关论文
共 109 条
[41]  
GUSHCHIN GL, 1997, J UROL S, V157, P311
[42]   Modulation of bladder α1-adrenergic receptor subtype expression by bladder outlet obstruction [J].
Hampel, C ;
Dolber, PC ;
Smith, MP ;
Savic, SL ;
Thüroff, JW ;
Thor, KB ;
Schwinn, DA .
JOURNAL OF UROLOGY, 2002, 167 (03) :1513-1521
[43]   Effect of permixon on human prostate cell growth: Lack of apoptotic action [J].
Hill, B ;
Kyprianou, N .
PROSTATE, 2004, 61 (01) :73-80
[44]   Pygeum africanum for the treatment of patients with benign prostatic hyperplasia:: A systematic review and quantitative meta-analysis [J].
Ishani, A ;
MacDonald, R ;
Nelson, D ;
Rutks, I ;
Wilt, TJ .
AMERICAN JOURNAL OF MEDICINE, 2000, 109 (08) :654-664
[45]   Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder - A randomized controlled trial [J].
Kaplan, Steven A. ;
Roehrborn, Claus G. ;
Rovner, Eric S. ;
Carlsson, Martin ;
Bavendam, Tamara ;
Guan, Zhonghong .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (19) :2319-2328
[46]   Silodosin, a new α1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia:: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men [J].
Kawabe, Kazuki ;
Yoshida, Masaki ;
Homma, Yukio .
BJU INTERNATIONAL, 2006, 98 (05) :1019-1024
[47]   DOXAZOSIN IN BENIGN PROSTATIC HYPERPLASIA - EFFECTS ON BLOOD-PRESSURE AND URINARY FLOW IN NORMOTENSIVE AND HYPERTENSIVE MEN [J].
KIRBY, RS .
UROLOGY, 1995, 46 (02) :182-186
[48]   Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The Prospective European Doxazosin and Combination Therapy (PREDICT) trial [J].
Kirby, RS ;
Roehrborn, C ;
Boyle, P ;
Bartsch, G ;
Jardin, A ;
Cary, MM ;
Sweeney, M ;
Grossman, EB .
UROLOGY, 2003, 61 (01) :119-126
[49]   CHARACTERIZATION AND LOCALIZATION OF PROSTATIC-ALPHA(1) ADRENOCEPTORS USING RADIOLIGAND RECEPTOR-BINDING ON SLIDE-MOUNTED TISSUE SECTION [J].
KOBAYASHI, S ;
TANG, R ;
SHAPIRO, E ;
LEPOR, H .
JOURNAL OF UROLOGY, 1993, 150 (06) :2002-2006
[50]   IS THE PROSTATE PILL FINALLY HERE [J].
LANGE, PH .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (17) :1234-1236